A RESTROSPECTIVE NON-INTERVENTIONAL STUDY AMONG PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS SWITCHING TO FINGOLIMOD OR TO OTHER DISEASE MODIFYING THERAPIES

被引：0
|
作者：
Medin, J. [1 ]
Haddad, P. [2 ]
Ricart, J. [3 ]
Lara, N. [4 ]
Pedros, M. [4 ]
Bizouard, G. [5 ]
Loefroth, E. [1 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
[3] Novartis Farmaceut SA, Barcelona, Spain
[4] IMS Hlth, Barcelona, Spain
[5] IMS Hlth RWE, Boulogne Billancourt, France
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.465
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND12
引用
收藏
页码：A427 / A427
页数：1
相关论文
共 50 条
  • [31] Olfactory dysfunction in patients with relapsing-remitting multiple sclerosis treated with disease modifying therapies
    Wnuk, M.
    Drabik, L.
    Marona, M.
    Szaleniec, J.
    Bryll, A.
    Karcz, P.
    Kolasinska, J.
    Kolasinska, M.
    Ziekiewicz, M.
    Skladzien, J.
    Popiela, T.
    Slowik, A.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 542 - 543
  • [32] Persistence with multiple sclerosis disease-modifying therapies is highest when switching to fingolimod compared with other oral and injectable therapies: a retrospective US claims database analysis
    Korn, Jonathan
    Medin, Jennie
    Fang, Juanzhi
    Putzki, Norman
    NEUROLOGY, 2017, 88
  • [33] Disease modifying therapies discontinuation in relapsing-remitting Multiple Sclerosis: a monocentric cohort study
    Pasca, M.
    Forci, B.
    Mechi, C.
    Mariottini, A.
    Barilaro, A.
    Massacesi, L.
    Repice, A. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 464 - 465
  • [34] Changing disease modifying therapy switching dynamics for relapsing-remitting multiple sclerosis patients
    Wakeford, C.
    Ye, X.
    Pike, J.
    Jones, E.
    Hadfield, A.
    Fam, S.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 330 - 330
  • [35] Prevalence of Treatment Interruptions for Disease Modifying Therapies among Patients with Multiple Sclerosis
    Lublin, F. D.
    Rossi, C.
    Le, H. H.
    Holiday, C.
    Lefebvre, P.
    Pilon, D.
    Keenan, A.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 201 - 202
  • [36] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
  • [37] Effectiveness of disease-modifying therapies in relapsing multiple sclerosis in south china
    Tao, V.
    Zhao, L.
    Au, C.
    Ng, A.
    Mok, V.
    Lau, A.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 531 - 532
  • [38] COST-UTILITY OF DISEASE MODIFYING THERAPIES FOR RELAPSING -REMITTING MULTIPLE SCLEROSIS
    Zimmermann, M.
    Brouwer, E.
    Tice, J. A.
    Seidner, M.
    Loos, A.
    Liu, S.
    Chapman, R. H.
    Kumar, V
    Carlson, J. J.
    VALUE IN HEALTH, 2017, 20 (05) : A193 - A193
  • [39] Two new oral disease modifying therapies in relapsing remitting multiple sclerosis
    Lebrun, C.
    de Seze, J.
    REVUE NEUROLOGIQUE, 2014, 170 (12) : 721 - 722
  • [40] FINGOLIMOD VERSUS TEIFLUNOMIDE: HEALTH CARE COSTS ASSOCIATED WITH PATIENTS DIAGNOSED WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TAKING DISEASE MODIFYING THERAPIES IN THE UNITED STATES
    Greene, M.
    Greene, N.
    VALUE IN HEALTH, 2016, 19 (03) : A69 - A69
12345